April 2 (Reuters) - Edgewise Therapeutics Inc EWTX.O:
EDGEWISE THERAPEUTICS ANNOUNCES POSITIVE TOP-LINE RESULTS FROM PHASE 2 CIRRUS-HCM FOUR-WEEK TRIAL OF EDG-7500 IN HYPERTROPHIC CARDIOMYOPATHY $(HCM)$
EDGEWISE THERAPEUTICS INC - EDG-7500 WAS GENERALLY WELL-TOLERATED
EDGEWISE THERAPEUTICS INC: INITIAL DATA READ-OUT FROM PART D IS EXPECTED IN SECOND HALF OF 2025
EDGEWISE: TRIAL SHOWED CLINICALLY MEANINGFUL REDUCTIONS IN LVOT GRADIENTS IN PARTICIPANTS WITH OBSTRUCTIVE HCM
EDGEWISE THERAPEUTICS INC - PHASE 3 INITIATION PLANNED FOR FIRST HALF OF 2026
Source text: ID:nPn7gBgQYa
Further company coverage: EWTX.O
((Reuters.Briefs@thomsonreuters.com;))
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.